Minimal-change glomerulonephritis associated with circulating anticoagulant to factor XII.

particularly difficult cases in whom standard treatment had failed. In three of them mexiletine alone controlled the arrhythmia, but only at the cost of intolerable adverse effects. Combined treatment with mexiletine and propranolol, which have different actions and different adverse effects, enables arrhythmia to be suppressed through co-operative antiarrhythmic action. Since adverse effects have been a major limitation to widespread use of mexiletine3 4combined therapy with propranolol may broaden its usefulness as an antiarrhythmic drug by two means-by decreasing its adverse effects and by more effective arrhythmia suppression through co-operative drug action.